New Delhi Metallo-Beta-Lactamase 1 (NDM-1)

New Delhi Metallo-Beta-Lactamase 1 (NDM-1) is a broad-spectrum Ambler Class B1 (Bush–Jacoby Group 3a) dizinc metallo-β-lactamase (MBL) encoded by the mobile blaNDM-1 gene (813 bp, encoding a 270-amino-acid polypeptide with a molecular mass of ~27.5 kDa). First identified in 2008 by Timothy Walsh, Yonghong Wang, and colleagues in a Klebsiella pneumoniae and Escherichia coli isolate recovered from a Swedish patient hospitalized in New Delhi, India, NDM-1 hydrolyzes the four-membered β-lactam ring of virtually all bicyclic β-lactam antibiotics—including penicillins, cephalosporins, and last-resort carbapenems (imipenem, meropenem, ertapenem, and doripenem)—sparing only the monobactam aztreonam.

Unlike Ambler Class A, C, and D β-lactamases (such as Klebsiella pneumoniae Carbapenemase (KPC)), which utilize an active-site serine (Ser70) to form a covalent acyl-enzyme intermediate, NDM-1 requires two divalent zinc cations (Zn²⁺) in its catalytic cleft to polarize a bridging hydroxide ion (OH−) for direct non-covalent nucleophilic attack on the β-lactam carbonyl carbon. Because it lacks a catalytic serine, NDM-1 is refractory to all clinically approved serine β-lactamase inhibitors—including clavulanate, sulbactam, tazobactam, avibactam, vaborbactam, and relebactam—making blaNDM-1 dissemination across Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii a major global threat in clinical antimicrobial resistance.

The αβ/βα Sandwich Fold and Zn1/Zn2 Coordination Spheres

High-resolution X-ray crystal structures of NDM-1 reveal the canonical metallo-β-lactamase αβ/βα four-layered sandwich fold, in which two central mixed β-sheets (composed of seven and five strands, respectively) are flanked by solvent-exposed α-helices. The shallow, plastic active-site groove sits at the bottom of the β-sandwich and is flanked by two flexible substrate-binding loops: Loop L3 (residues 63–73, containing a hydrophobic cluster around Met67, Pro68, Val73, and Trp93) and Loop L10 (residues 208–226, containing Lys211, Asp212, and Asn220).

Within the active site, two Zn²⁺ ions (Zn1 and Zn2, separated by ~3.5–4.2 Å depending on substrate binding) are coordinated by six strictly conserved side chains (numbered according to the standard Class B β-lactamase BBL numbering scheme):

• The Zn1 (3H) Site: Tetrahedrally coordinated by three histidine residues—His120, His122, and His189—plus the bridging hydroxide nucleophile (OH− / water).
• The Zn2 (DCH) Site: Coordinated by Asp124, Cys208, and His250, together with the bridging hydroxide ion and an apical solvent molecule.

When a carbapenem or cephalosporin enters the wide active-site cleft, Zn1 and Asn220 polarize the C7/C6 carbonyl oxygen of the β-lactam ring, while the carboxylate group at C3/C4 of the bicyclic core forms an electrostatic salt bridge with Zn2 and Lys211. The bridging hydroxide ion (pK_a depressed to ~5.5–6.0 by bridging both Lewis-acidic Zn²⁺ centers) attacks the electrophilic β-lactam carbonyl carbon to generate a transient, negatively charged tetrahedral oxyanion intermediate stabilized by Zn1 and Asn220. Cleavage of the C–N amide bond produces a ring-opened anionic intermediate in which the leaving ring nitrogen sits coordinated to Zn2 until bulk water protonates the nitrogen and regenerates the bridging hydroxide, achieving catalytic efficiencies (k_cat/K_m) of 10⁵ to 10⁶ M⁻¹ s⁻¹ against imipenem and meropenem.

Epistatic Loop Networks and Outer-Membrane Lipoprotein Anchoring

What sets NDM enzymes apart from soluble periplasmic metallo-β-lactamases (VIM-2 and IMP-1) is an evolutionary adaptation to host nutritional immunity. During human infection, neutrophils release calprotectin (S100A8/S100A9), a divalent-metal-chelating protein that sequesters extracellular and periplasmic Zn²⁺ and Mn²⁺ down to sub-nanomolar concentrations. Soluble VIM and IMP enzymes rapidly lose their more weakly bound Zn2 cofactor (K_d in the micromolar range) in the presence of calprotectin, whereupon the apo-proteins misfold and are degraded by periplasmic proteases (DegP/Prc).

In contrast, NDM-1 contains a canonical N-terminal Type II prokaryotic signal peptide lipobox (Leu15–Ser16–Gly17–Cys26) followed by an amphipathic α-helical tether containing Trp28. Signal peptidase II cleaves the leader peptide and diacylglyceryl transferase lipidates Cys26, anchoring NDM-1 directly to the inner leaflet of the Gram-negative outer membrane. Membrane anchoring shields apo-NDM from periplasmic proteolysis and allows NDM-1 to be packaged into outer membrane vesicles (OMVs)—secreted lipid nanoparticles that hydrolyze β-lactams extracellularly and protect neighboring susceptible bacteria in polymicrobial biofilms. Furthermore, clinical evolution under zinc starvation has selected over 60 natural blaNDM allele variants (notably NDM-4 M154L, NDM-5 V88L + M154L, and NDM-14 D130G). Guided by direct coupling epistasis across the active-site frame (W93–D124–K211–N220), the Met154Leu substitution rigidifies the second-shell α-helix supporting His122, increasing Zn2 binding affinity 3-fold to 5-fold and preserving high-level carbapenem resistance even under intense calprotectin zinc chelation.

Chimeric Origin in Acinetobacter and Tn125 / IS26 Mobilization

Sequence forensics and bioinformatics alignments revealed that blaNDM-1 originated in an environmental Acinetobacter species through an in-frame chimeric fusion event: the first 19 nucleotides of blaNDM-1 (encoding the N-terminal lipoprotein signal peptide) were captured from the aminoglycoside phosphotransferase gene aphA6, situated downstream of an ISAba125 insertion sequence (which supplies the strong −35 TTGAAT promoter hexamer driving constitutive blaNDM-1 transcription).

In Acinetobacter baumannii, blaNDM-1 is mobilized within the 10,099-bp composite transposon Tn125, bracketed by two direct copies of ISAba125 and consistently carrying the downstream bleomycin resistance gene bleMBL (encoding the 121-aa bleomycin-binding protein BRP_MBL, which co-stabilizes the bicistronic blaNDM-1–bleMBL mRNA) along with trpF (phosphoribosylanthranilate isomerase), dsbD/tat, cutA, groES, and groEL. Upon jumping via horizontal gene transfer into Enterobacterales (K. pneumoniae, E. coli, Enterobacter cloacae), the ancestral Tn125 structure is frequently truncated and captured by IS26, ISCR1 rolling-circle elements (linked to sul1 and Class 1 integrase intI1), and Tn3000 transposons on self-conjugative IncX3, IncFII, IncA/C2, and IncL/M plasmid replicons.

Chromosomal tRNA Island Integration and Compositional Divergence

In addition to autonomous plasmid carriage, clinical surveillance of intensive care unit (ICU) outbreaks demonstrates that IS26 and ISCR1/intI1 arrays can integrate the entire blaNDM-1–bleMBL–trpF–sul1–qacEΔ1–intI1 resistance cassette directly into chromosomal tRNA loci (tRNA-Phe, tRNA-Ser, tRNA-Arg) or phage attachment sites in Klebsiella pneumoniae and Pseudomonas aeruginosa. Because this exogenous resistance island carries a distinct oligonucleotide signature and GC composition relative to the host chromosome, sliding-window tetranucleotide Kullback–Leibler divergence (D_KL) and compositional Z-score scanning detect chromosomal blaNDM-1 islands as sharp genomic anomalies (Z > +5.0 SD, 7.4× above housekeeping baseline)—recovering outbreak transmission links that standard 7-gene multilocus sequence typing (MLST) or ribosomal RNA (16S rRNA) profiling completely miss.

Phenotypic EDTA Synergy and Rapid Molecular Detection

In clinical microbiology laboratories, distinguishing a metallo-β-lactamase producer (NDM, VIM, IMP) from a serine carbapenemase producer (KPC, OXA-48) is urgent for antimicrobial stewardship. Phenotypic confirmation relies on metal chelators: in the modified Carbapenem Inactivation Method (mCIM) paired with eCIM, adding 5 mM ethylenediaminetetraacetic acid (EDTA) or dipicolinic acid strips the catalytic Zn²⁺ ions from NDM-1, restoring a ≥5 mm meropenem zone of inhibition around the indicator E. coli ATCC 25922 lawn (whereas serine KPC and OXA-48 enzymes remain unaffected by EDTA). Rapid point-of-care confirmation is achieved within 15–45 minutes using lateral flow immunochromatographic assays (NG-Test CARBA 5) or multiplex real-time PCR (Xpert Carba-R) targeting blaNDM, blaKPC, blaVIM, blaIMP, and blaOXA-48.

Aztreonam–Avibactam, Cefiderocol, and Bicyclic Boronates

Because NDM-1 cannot hydrolyze the monocyclic β-lactam ring of aztreonam, yet clinical blaNDM-1 isolates almost invariably co-harbor plasmid-encoded Extended-Spectrum β-Lactamases (ESBLs such as CTX-M-15) or AmpC (CMY-2) cephalosporinases that destroy aztreonam, clinicians employ a dual rational combination: aztreonam–avibactam (or co-administration of ceftazidime–avibactam plus aztreonam). In this regimen, the diazabicyclooctane (DBO) inhibitor avibactam covalently inhibits all co-expressed Class A (CTX-M, KPC), Class C (AmpC), and Class D (OXA-48) serine β-lactamases, shielding aztreonam so it can reach and acylate Penicillin-Binding Protein 3 (PBP3) uninhibited by NDM-1.

Alternative therapeutic options include:

1. Cefiderocol: A catechol-substituted siderophore cephalosporin that binds ferric iron (Fe3+) to enter the periplasm via bacterial TonB-dependent iron transporters ("Trojan horse" uptake) and carries bulky C3/C7 side chains that resist hydrolysis by both NDM-1 and serine carbapenemases.
2. Dual Serine/Metallo Cyclic Boronates (Taniborbactam / VNRX-5133 and Xeruborbactam / QPX7728): Next-generation bicyclic boronate inhibitors whose boron atom mimics the tetrahedral oxyanion transition state in both serine β-lactamases (forming a covalent bond with Ser70) and Class B1 MBLs (coordinating directly between Zn1 and Zn2 in NDM-1 with nanomolar inhibition constants, K_i ≈ 1–80 nM).

Why are avibactam, vaborbactam, and clavulanic acid completely ineffective against NDM-1?

Classical β-lactamase inhibitors (clavulanate, tazobactam) and modern serine carbapenemase inhibitors (avibactam, vaborbactam, relebactam) work by forming a covalent bond with the nucleophilic hydroxyl group of an active-site serine residue (Ser70). Because NDM-1 is a Class B1 metallo-β-lactamase that lacks a catalytic serine and instead uses two Zn²⁺ ions to activate a non-covalent water/hydroxide molecule, serine-targeted inhibitors cannot react with or block the NDM-1 active site.

How does the aztreonam–avibactam combination kill NDM-1-producing bacteria?

Monobactams like aztreonam have a single monocyclic β-lactam ring rather than a bicyclic ring system, which prevents proper productive binding to the Zn2 site of NDM-1—making aztreonam stable against NDM-1 hydrolysis. However, NDM-1-producing bacteria almost always carry additional serine β-lactamases (CTX-M-15 or AmpC) on the same plasmid that destroy aztreonam. Pairing aztreonam with avibactam neutralizes the co-carried serine β-lactamases, allowing aztreonam to cross the periplasm intact and inhibit cell-wall synthesis at PBP3.

Why does outer-membrane lipidation give NDM-1 an evolutionary advantage over VIM and IMP enzymes?

During human infection, host neutrophils secrete calprotectin to starve bacteria of free zinc (Zn2+). Soluble periplasmic metallo-β-lactamases (VIM-2 and IMP-1) lose their catalytic zinc ions under zinc starvation and are rapidly degraded by bacterial periplasmic proteases. Because NDM-1 is lipidated at Cys26 and anchored to the inner leaflet of the outer membrane (and packaged into secreted outer membrane vesicles), it resists periplasmic protease degradation and continues to protect the bacterial population during host nutritional immunity.

1. Yong, D., Toleman, M. A., Giske, C. G., Cho, H. S., Sundman, K., Lee, K., & Walsh, T. R. (2009). "Characterization of a new metallo-β-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India." Antimicrobial Agents and Chemotherapy, 53(12), 5046–5054. https://doi.org/10.1128/AAC.00774-09
2. King, D. T., Worrall, L. J., Gruninger, R., & Strynadka, N. C. J. (2012). "New Delhi metallo-β-lactamase: structural insights into β-lactam recognition and inhibition." Journal of the American Chemical Society, 134(28), 11362–11365. https://doi.org/10.1021/ja303579d
3. González, L. J., Bahr, G., Nakashige, T. G., Nolan, E. M., Bonomo, R. A., & Vila, A. J. (2016). "Membrane anchoring stabilizes and favors secretion of New Delhi metallo-β-lactamase." Nature Chemical Biology, 12(7), 516–522. https://doi.org/10.1038/nchembio.2083
4. Bahr, G., González, L. J., & Vila, A. J. (2021). "Metallo-β-lactamases in the age of multidrug resistance: from structure and mechanism to evolution, dissemination, and inhibitor design." Chemical Reviews, 121(13), 7957–8094. https://doi.org/10.1021/acs.chemrev.1c00138